(NEW YORK) — Here are today’s In Crisis headlines:
COVID-19 numbers
Here’s the latest data on COVID-19 coronavirus infections and deaths.
Latest reported numbers globally per Johns Hopkins University
Global diagnosed cases: 40,464,761
Global deaths: 1,119,369. The United States has the most deaths of any single country, with 220,134.
Number of countries/regions: at least 188
Total patients recovered globally: 27,738,284
Latest reported numbers in the United States per Johns Hopkins University
There are at least 8,215,605 reported cases in 50 states + the District of Columbia, Puerto Rico and Guam. This is more than in any other country.
U.S. deaths: at least 220,134. New York State has the greatest number of reported deaths in the U.S., with 33,366.
U.S. total patients recovered: 3,272,603
U.S. total people tested: 126,033,173
The greatest number of reported COVID-19 cases in the U.S. is in California, with 880,334 confirmed cases out of a total state population of 39.51 million. That ranks third in the world after Maharashtra, India, which has 1,601,365 reported cases, and Sao Paulo, Brazil, which has 1,064,039 reported cases.
Now over 220,000 COVID-19 deaths in the US
The United States now has more than 220,000 reported deaths from COVID-19, according to the latest data compiled by Johns Hopkins University. As of Tuesday morning, the total number of cases stood at 220,134, representing just under 20% of the reported 1,119,369 global deaths – more deaths than in any another country. The latest forecast from the Centers for Disease Control and Prevention estimates there will be from 229,000 to 240,000 COVID-19 deaths in the U.S. by the week ending November 7.
The updated deaths tally comes as COVID-19 cases across the U.S. continue to surge. ABC News analyzed state coronavirus trends across all 50 states, Washington D.C., and Puerto Rico and found there were increases in cases in 39 states, increases in the daily rate of positivity in 27 states, increases in hospitalizations in 41 states, and increases in daily deaths in 13 states. In the past week alone, the U.S. has recorded nearly 385,898 new coronavirus cases — reporting two days with over 60,000 cases — the highest daily figures seen since late July.
New CDC guidance “strongly recommends” wearing a mask on airplanes, subways, taxis
Citing increased virus transmission from people traveling, the Centers for Disease Control and Prevention on Monday issued new guidance that “strongly recommends” that everyone wear masks while on public transportation. “CDC strongly recommends appropriate masks be worn by all passengers and by all personnel operating the conveyance while on public conveyances (e.g., airplanes, ships, ferries, trains, subways, buses, taxis, ride-shares) and within locations where people board such conveyances (e.g. airports, bus or ferry terminals, train stations, seaports),” the agency writes on its website. “Transmission of the virus through travelers has led to — and continues to lead to — interstate and international spread of the virus which causes COVID-19,” the CDC warns, adding that the guidance’s goal is to “mitigate further introduction and spread of COVID-19, and help safely re-open America’s economy.” The CDC notes that some exemptions are allowed, such as being under the age of two or possessing a note from a doctor explaining a medical condition.
Another potential COVID-19 vaccine anticipating authorization request before year’s end
Pharmaceutical manufacturer Moderna is anticipating they could request emergency authorization use in the U.S. for their in-development COVID-19 vaccine by December. Moderna Chief Executive Stéphane Bancel tells The Wall Street Journal that it depends upon whether the company gets positive interim results in November from their ongoing phase 3 clinical trial, which began in July and involves some 30,000 volunteers. If the interim results take longer to gather, the authorization request would likely come early in 2021.
Pharmaceutical giant Pfizer said Friday they anticipate applying for emergency authorization use in the U.S. “in the third week of November,” if their ongoing phase 3 trial meets three benchmarks: proof of effectiveness, proof of safety, and “manufacturing data that demonstrates the quality and consistency of the vaccine that will be produced.”
According to The New York Times, there are currently 11 ongoing phase 3 human trials of potential COVID-19 vaccines. Pharmaceutical giants Johnson & Johnson and Eli Lilly recently paused their phase 3 vaccine trials after a participant in each experienced an unexpected, unspecified illness.
Copyright © 2020, ABC Audio. All rights reserved.